Luis Paz-Ares

Luis Paz-Ares is the principal investigator of the IMpower133 trial that established atezolizumab plus carboplatin-etoposide as a standard of care for extensive-stage SCLC, achieving the first survival improvement in this setting in over two decades. He has led pivotal trials in NSCLC and SCLC across multiple histologies and molecular subtypes. His research program spans novel immunotherapy combinations, biomarker development, and treatment resistance in thoracic oncology. He is a key author of ESMO lung cancer guidelines and the most cited thoracic oncologist in Spain.